SCYNEXIS (SCYX) Q1 2025 earnings summary

Executive summary

• FDA lifted clinical hold on ibrexafungerp's Phase 3 MARIO study in April 2025; SCYNEXIS is reinitiating the study despite GSK's notice to terminate, leading to a dispute over milestone payments.

• Hansoh received Chinese approval for ibrexafungerp in acute VVC, triggering milestone and future royalty payments for SCYNEXIS.

• Positive preclinical data for SCY-247 presented; Phase 1 data expected Q3 2025.

• Ongoing class action and derivative lawsuits allege misleading statements regarding manufacturing controls and clinical study risks.

Financial highlights

• Q1 2025 revenue was $0.3 million, down from $1.4 million in Q1 2024, mainly due to lower GSK license agreement revenue.

• Net loss for Q1 2025 was $5.4 million, or $(0.11) per share, compared to net income of $0.4 million, or $0.01 per share, in Q1 2024.

• Research and development expenses decreased 29% year-over-year to $5.1 million.

• Selling, general, and administrative expenses were stable at $3.7 million.

• Total other income was $3.2 million, down from $10.5 million in Q1 2024, mainly due to lower warrant liability fair value adjustment.

Outlook and guidance

• Management believes current capital resources are sufficient for at least 12 months, with cash runway projected into Q3 2026, but anticipates the need for additional funding due to ongoing R&D and SG&A expenses.

• Initial Phase 1 data for SCY-247 anticipated in Q3 2025.

• Future capital needs depend on milestone achievement under the GSK agreement, clinical progress, and potential regulatory outcomes.

• Plans to resume enrollment in the MARIO study in the coming weeks.